Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: A pilot study

Journal of Infectious Diseases

Volumn 184, Issue 2, 2001, Pages 196-200

  Spruance, Spotswood L ^a   Tyring, Stephen K ^b   Smith, Michael H ^c   Meng, Tze Chiang ^d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Division of Biostatistics   (United States)

^d 3M COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; RESIQUIMOD; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SKIN INFLAMMATION;

ADULT; BIOLOGICAL RESPONSE MODIFIERS; DOUBLE-BLIND METHOD; FEMALE; GELS; HERPES GENITALIS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PILOT PROJECTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; TREATMENT OUTCOME;

EID: 0035879830     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/322007     Document Type: Article

References (14)

1. Herpes simplex virus type 2 in the United States, 1976-1994
2. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women: A multicenter, double-blind, placebo-controlled trial
3. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection
4. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study
5. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection
6. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir
7. Prospects for control of herpes simplex virus disease through immunization
8. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
9. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial
10. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment
11. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod
12. Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848
13. Cytokine induction in mice by the immunomodulator imiquimod
14. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs